TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02262507

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device Wearing
Description: Q30 collar - collar designed to be worn around the neck to apply slight pressure to jugular veins. Each subject will undergo repeat oto-acoustic measures both wearing the device and not wearing the device
Study: NCT04677335

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AB-LIFE with Monacolin K
Description: Red yeast rice extract (also known by its scientific name, Monascus purpureus) certified to contain 10 mg of monacolin K, plus 1 billion total cfu of AB-LIFE probiotic formula, which is composed of 3 Lactoplantibacillus plantarum (formerly known as Lactobacillus plantarum) strains: CECT7527 (also known as KABP011™), CECT7528 (also known as KABP012™) and CECT7529 (also known as KABP013™), all in a maltodextrin carrier. Capsules are of vegetable origin (hydroxypropylmethyl cellulose).
Study: NCT02738606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Description: Undergo lung metastasectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metastasectomy
Description: Undergo lung metastasectomy
Study: NCT00865722

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Remote Postconditioning
Description: Lower limb compression using a cuff inflated to 200 mmHg for 5 ' followed by 5' of reperfusion fo three times during 30'

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Postconditioning
Description: Lower limb compression using a cuff inflated to 200 mmHg for 5 ' followed by 5' of reperfusion fo three times during 30'
Study: NCT03304899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RiaSTAP Injectable Product
Description: RiaSTAP, Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes.~Dose (mg/kg body weight) =~(\[Target level (mg/dL) - measured level (mg/dL)\])/(1.7 (mg/dL per mg/kg body weight))

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RiaSTAP Injectable Product
Description: RiaSTAP, Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes.~Dose (mg/kg body weight) =~(\[Target level (mg/dL) - measured level (mg/dL)\])/(1.7 (mg/dL per mg/kg body weight))
Study: NCT03019627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGF
Description: Eye Drop 20 μg/mL

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Eye Drop
Study: NCT00418691

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IR Methylphenidate
Description: 10 mg by mouth (PO) twice daily x 4 Weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: 200 mg PO Once Daily x 4 Weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SR Methylphenidate
Description: 18 mg PO Once Daily x 4 Weeks
Study: NCT01369875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg/day X 2 days intravenous (IV) over 1 hour on days -7 and -6
Study: NCT02738606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo hepatectomy
Study: NCT01359774

Intervention type: OTHER
Group type: OTHER
Intervention: 31P-MR spectroscopy
Description: Brain energy deficit is quantified using 31P-MR spectroscopy

Intervention type: OTHER
Group type: OTHER
Intervention: 31P-RMN spectroscopy
Description: Brain energy deficit is quantified using 31P-RMN spectroscopy
Study: NCT04964076

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04677335

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules containing maltodextrin carrier only. Capsules are of vegetable origin (hydroxypropylmethyl cellulose).
Study: NCT01276340

Intervention type: DEVICE
Intervention: KEAT stimulator
Description: electrical stimulation with KEAT stimulator : 4 times per week during 2 months
Study: NCT04709562

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Velocity Nasal Insufflation (HVNI)
Description: The purpose of this intervention is to evaluate the efficacy of HVNI in clinically stabilizing patients presenting with hypercapnic respiratory distress.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive Positive Pressure Ventilation (NIPPV)
Description: The purpose of this intervention is to evaluate the efficacy of NIPPV in clinically stabilizing patients presenting with hypercapnic respiratory distress.
Study: NCT04412356

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tracheotomy
Description: Surgical procedure to secure airway

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheotomy
Description: Surgical procedure to secure airway
Study: NCT03097627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG Intervention
Description: The intervention to be administered is the drug indocyanine green.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Camera
Description: The intervention to detect the administered drug, indocyanine green.
Study: NCT02003404

Intervention type: DEVICE
Intervention: Control Abdominal Skin
Description: Three barrier materials will be peeled from abdominal skin after a set period at a set rate.

Intervention type: DEVICE
Intervention: Peristomal Abdominal Skin
Description: Three barrier materials will be peeled from abdominal skin after a set period at a set rate.
Study: NCT04214977

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia for Anorectal Surgeries in Prone Position
Description: Spinal anesthesia in sitting position was done under complete aseptic technique through a standard midline approach. One and a half millilitres of 0.5% bupivacaine (7.5 mg) was injected through a 25 Gauge pencil-point needle into the subarachnoid space at L3-L4 or L4-L5 interspace. All patients were kept in a head-up position for 3 minutes. The patient was then asked to turn him- or herself into the prone position on the surgical table with the help of the surgical and anesthetic teams.
Study: NCT02429830

Intervention type: DEVICE
Group type: OTHER
Intervention: LINX device
Description: The LINX device is a permanent implant placed at the area of the lower esophageal sphincter (LES) and is designed to augment a weak LES and minimize or eliminate GERD-related symptoms.
Study: NCT04323072

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wide antrectomy
Description: The starting point of resection of the stomach from the pylorus to begin the gastrectomy is 2 cm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Smal antrectomy
Description: The starting point of resection of the stomach from the pylorus to begin the gastrectomy is 6 cm.
Study: NCT02033746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Han's Acupoint Nerve Stimulator
Description: frequency delivery(3 seconds of 2 Hz followed by 3 seconds of 100 Hz(dense disperse method).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Han's Acupoint Nerve Stimulator
Description: frequency delivery(3 seconds of 2 Hz followed by 3 seconds of 100 Hz(dense disperse method).
Study: NCT01800591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Study: NCT02001935

Intervention type: DRUG
Group type: OTHER
Intervention: theophylline
Description: After oral theophylline 200mg per day for two weeks,bood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2 and CYP2E1
Study: NCT04585841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Patients will receive cannabidiol in the period of time they receive chemotherapy.
Study: NCT02450513

Intervention type: DRUG
Intervention: Adalimumab
Description: 160 mg at week 0, 80 mg at week 2 and 40 mg every two weeks onwards
Study: NCT02145117

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MBSR
Description: Behavioral
Study: NCT00078247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir
Description: 300 mg tablet taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir
Description: 300 mg tablet taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: 300 mg tablet taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: 300 mg tablet taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: 300 mg tablet taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: 300 mg tablet taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuberculosis treatment
Description: Tuberculosis treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuberculosis treatment
Description: Tuberculosis treatment
Study: NCT01947764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HADITHI Intervention
Description: The HADITHI Intervention consists of a culturally adapted, multi-component clinic-based intervention designed to support families in pediatric HIV disclosure in Kenya.~In addition to the Usual Care components, the HADITHI Intervention clinics will have the following intervention components:~Culturally modified curricula materials, including videotaped narratives, to guide counseling and group sessions.~Dedicated disclosure counselors to initiate and conduct disclosure, with one-on-one counseling for caregivers and children, as well as family-based sessions.~Post-disclosure peer support groups, facilitated by the disclosure counselors, for children who have gone through disclosure.
Study: NCT01789437

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Intravitreal Implant (Ozuredex)
Study: NCT01385657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A total of 4 doses were administered.
Study: NCT01369875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg/day X 2 days intravenous (IV) over 1 hour on days -7 and -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 720,000 IU/kg intravenous (IV) over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
Study: NCT01385657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: A total of 4 doses were administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: A total of 4 doses were administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background treatment
Description: Participants were required to apply stable doses of an additive-free, basic bland emollient on the affected areas of the skin twice daily throughout the study.
Study: NCT04214977

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General Anesthesia Using Laryngeal Mask Airway for Anorectal Surgeries in Prone Position
Description: General anesthesia was induced using fentanyl 2 mcg/kg and Propofol 2-3 mg/kg. Any stomach contents were then suctioned through an oro-gastric tube to reduce the risk of regurgitation. Proper (weight-based) classic laryngeal mask airway was then blindly inserted. laryngeal mask airway was then properly fixed to the face and anesthesia was maintained with isoflurane 1-2% in 50% Oxygen/air mixture.
Study: NCT01385657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background treatment
Description: Participants were required to apply stable doses of an additive-free, basic bland emollient on the affected areas of the skin twice daily throughout the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background treatment
Description: Participants were required to apply stable doses of an additive-free, basic bland emollient on the affected areas of the skin twice daily throughout the study.
Study: NCT02404818

Intervention type: PROCEDURE
Intervention: Cardiac Magnetic Resonance Imaging
Description: A cardiac MRI will be performed.

Intervention type: PROCEDURE
Intervention: Echocardiogram
Description: An echocardiogram will be performed for the following information: M-mode, two-dimensional, Doppler blood flow measurements, and longitudinal strain and strain rate imaging
Study: NCT06284083

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: taking a blood sample
Description: Blood samples collected from patienst, only 7 mL
Study: NCT00188058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Setting of positive end-expiratory pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Setting of positive end-expiratory pressure
Study: NCT02403427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VoiceDiab expert system
Description: Decision support system VoiceDiab this is computer-based system constructed for mobile phone devices working on the server.~Patients in experimental arm get the mobile phone application for 4 days. Glucose control will be done by two methods SMPG and CGM. Before every study's meal insulin dose with type of bolus will be indicate by VoiceDiab.
Study: NCT01842412

Intervention type: BEHAVIORAL
Intervention: exercise
Description: one bout of exercise training

Intervention type: BEHAVIORAL
Intervention: exercise
Description: one bout of exercise training
Study: NCT01369875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 720,000 IU/kg intravenous (IV) over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
Study: NCT02177370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenoterol MDI
Study: NCT02790801

Intervention type: OTHER
Intervention: observation
Description: observation
Study: NCT01756196

Intervention type: DRUG
Intervention: Spinal Steroid Injection
Description: Steroid Injection
Study: NCT01420926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study: NCT02711631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MedBIKE
Description: MedBIKE is an exercise cardiac rehabilitation system that allows participants to perform clinical cardiac rehabilitation at home or at a local center, instead of having to travel to the hospital. It provides a high level of physiological monitoring to allow patient safety to be continually monitored while exercising.
Study: NCT01354210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Text Message Reminder
Description: Daily
Study: NCT04631354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radio-labelled S-770108
Description: 99mTc radio-labelled S-770108 supplied as a capsule containing 6 mg active pirfenidone for inhalation
Study: NCT02177370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DSCG MDI
Study: NCT00835861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Women randomized to the Experimental arm will receive standard diet and glucose self-monitoring education. They will be initiated on Metformin 500 BID if they were medication naïve, or will be continued on their current dosage of Metformin if they were taking it prior to pregnancy. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to a maximum of 2250mg/day to achieve target glycemic control. If glycemic control can not be achieved with Metformin as a single agent insulin will be added.
Study: NCT01420926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02181114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expert System Coaching
Description: Patients will receive coaching and feedback over the phone and stag-appropriate educational materials (i.e. paphlets, brochures, personalized feedback report) based on their answers to the survey questions and where they are in their kidney transplant evaluation process.
Study: NCT03121365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital/E-Book Arm
Description: Promotion of early reader digital e-book reading

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard/Board Book Arm
Description: Promotion of early reader board book reading
Study: NCT00269919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone Long-Acting Injectable (RLAI)
Description: The RLAI 25 mg or 37.5 mg or 50 mg will be administered intramuscularly depending on Investigator's discretion every 2 weeks for 2 years.
Study: NCT03626961

Intervention type: OTHER
Intervention: readmission
Description: Readmission after 48 hours

Intervention type: OTHER
Intervention: readmission
Description: Readmission after 48 hours

Intervention type: OTHER
Intervention: discharge
Description: Discharge

Intervention type: OTHER
Intervention: discharge
Description: Discharge
Study: NCT04254666

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical Literacy & Food Literacy Intervention.
Description: A 12-week intervention designed to expose adolescents with ID to a variety of sports skills and healthy eating concepts to equip them with skills and confidence to participate in sports and make healthy food choices. The program will follow a protocol adapted to meet the needs of a diverse group of children with ID. Sessions will be held 1 time/week for 75 minutes virtually; 35 minutes will focus on sport skills activities with 35 minutes devoted to healthy eating.
Study: NCT02656355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight shift training and APA feedback
Description: Use COP trajectory to train weight shift on force plate. To give APA visual feedback for subjects after weight shift training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight shift training without APA feedback
Description: Use COP trajectory to train weight shift on force plate.
Study: NCT01370265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson
Description: Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson
Description: Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-13 ammonia
Description: Ammonia N-13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. The N-13 ammonia used in the study was synthesized by the Mayo Cyclotron Facility as per routine institutional clinical protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-13 ammonia
Description: Ammonia N-13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. The N-13 ammonia used in the study was synthesized by the Mayo Cyclotron Facility as per routine institutional clinical protocol.
Study: NCT01369875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes
Description: Intravenous (IV) over 30 minutes on day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes
Description: Intravenous (IV) over 30 minutes on day 0
Study: NCT00386256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Health Buddy, Home telehealth technology
Description: Exercise questions, educational messages, and clinical reminders have been programmed into the home telehealth technology and are administered daily via the Health Buddy(R) to evaluate the program's feasibility based on adherence rates, program completion rates, and safety.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Health Buddy, Home telehealth technology
Description: Exercise questions, educational messages, and clinical reminders have been programmed into the home telehealth technology and are administered daily via the Health Buddy(R) to evaluate the program's feasibility based on adherence rates, program completion rates, and safety.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone counseling